Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalating-dose oral ivermectin in children with scabies weighing 5 to <15 kg
PACTR202107598843502Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Feb 2022
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in scabies comparing Escalating-dose oral ivermectin, Placebo comparator and Permethrin cream comparator/intervention (3 arms). Primary endpoint: Pruritus. Started Feb 2022; status: completed.
02
Drugs
ivermectinpermethrin
03
Conditions
scabies
Beyond the preview
Go deeper on PACTR202107598843502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202107598843502.